Durvalumab, an IgG1 kappa anti-PD-L1 monoclonal human antibody, in combination with etoposide and either carboplatin or cisplatin has been recently approved by FDA as first-line treatment of patients with ES-SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.